Skip to main content
31, Oct 2022

Plexision Aims to Deliver Single-Day Results for Organ Transplant Rejection Testing With Antigen Dx

NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an antigen-based blood test for early signs a patient's immune system is attacking the donated tissue.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.